Duchenne Muscular Dystrophy Treatment Market Insights and Forecast to 2025Posted by rekha on November 28th, 2019 “The Global Duchenne Muscular Dystrophy Treatment Market increasing at a notable CAGR over the forecast period 2019-2025 to reach US$ 2,643.9 Mn by 2025 owing to grow in incidence of duchenne muscular dystrophy across the globe.” Precision Business Insights (PBI) in its report titled “Global Duchenne Muscular Dystrophy Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. The global duchenne muscular dystrophy treatment market was accounted for US$ XX Mn in 2018 and burgeoning at prominent growth rate over the forecast period 2019-2025 owing to surge in incidence of duchenne muscular dystrophy across the globe. For instance, according to National Organization for Rare Disorders, approximately 1 in 3,500 male births affected with DMD syndrome throughout the world. Moreover, strong R&D exposure by the market players for the development of newer drugs, promising product pipeline, fundraising from public and private sectors for the orphan diseases, and advanced healthcare services in developed and developing countries are propel the global duchenne muscular dystrophy treatment market. However, stringent regulations for the product approval, high cost of DMD treatment, lack of disease awareness in underdeveloped countries, and patent expiry of blockbuster drugs are expected to hamper the market. Global duchenne muscular dystrophy treatment market segmented on the basis of drug class, therapy type, distribution channel, and region Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=17193 Mutation Suppression Expected to Dominate the Global Duchenne Muscular Dystrophy Treatment Market Based on the therapy type, global duchenne muscular dystrophy treatment market segmented into mutation suppression, exon skipping, and others. Among all the therapies, mutation suppression dominated the global duchenne muscular dystrophy treatment market in 2018 and projected to grow at significant CAGR over the forecast period owing to better results with the mutation therapy due to targeting the specific mutation. Moreover, rise in R&D for the development of newer products also surge the market over the forecast years. For instance, in September 2016, Sarepta Therapeutics received FDA approval for Exondys 51 (eteplirsen) injection to treat patients with Duchenne muscular dystrophy. North America Leads the Global Duchenne Muscular Dystrophy Treatment Market PBI’s global duchenne muscular dystrophy treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for largest revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to increase in the prevalence of DMD disease in USA and Canada, rise in awareness about the disease among healthcare professionals, favorable reimbursement policies, and rise in healthcare expenditure are propel the market. Asia Pacific duchenne muscular dystrophy treatment market anticipated to exhibit substantial growth over the forthcoming years due to entry of market players into developing countries such as India and China and advanced healthcare infrastructure in the region. Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players Global duchenne muscular dystrophy treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region.
Key player’s profiles in the report are Bristol-Myers Squibb, FibroGen, Inc , ITALFARMACO S.p.A., Catabasis Pharmaceuticals, Inc., NS Pharma, Inc., Marathon Pharmaceuticals, LLC, ReveraGen BioPharma, Inc., Pfizer, Summit Therapeutics plc, Taiho Pharmaceutical Co, Sarepta Therapeutics, Inc., Santhera Pharmaceuticals, PTC Therapeutics. Detailed Segmentation By Drug Class o NSAIDs o Corticosteroids o Others By Therapy Type o Mutation Suppression o Exon Skipping o Others By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies Geography o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/global-duchenne-muscular-dystrophy-treatment-market/ Like it? Share it! More by this author |